

Lisa Salvatore

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9031068/lisa-salvatore-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

3,467
citations

28
h-index

58
g-index

96
ext. papers

3,992
ext. citations

5.5
avg, IF

4.25
L-index

#	Paper	IF	Citations
85	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
84	Management of single pulmonary metastases from colorectal cancer: State of the art.. <i>World Journal of Gastrointestinal Oncology</i> , 2022 , 14, 820-832	3.4	1
83	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021 , 30, 2455	3.9	1
82	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021 , 11, 712053	5.3	3
81	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , 2021 , 13,	6.6	2
80	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. <i>Cancers</i> , 2021 , 13,	6.6	1
79	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102202	14.4	4
78	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	4
77	A Novel Pathogenic Variant in an Italian Woman with Gallbladder Cancer. <i>Genes</i> , 2021 , 12,	4.2	0
76	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
75	Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	1
74	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
73	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 219-225	3.8	16
72	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020 , 5, e001001	6	3
71	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020 , 20, 683	4.8	26
70	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
69	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 191-199.e6	3.8	10

68	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599	8.7	14
67	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019 , 109, 175-182	7.5	17
66	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the BRAF BeCoolS study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
65	PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. <i>Cancers</i> , 2019 , 11,	6.6	30
64	Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3554-3554	2.2	
63	Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERPINA Study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3556-3556	2.2	
62	Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15039-e15039	2.2	
61	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3550-3550	2.2	1
60	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3540-3540	2.2	
59	Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3558-3558	2.2	
58	Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15038-e15038	2.2	
57	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-11	3.6	
56	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e471-e488	3.8	4
55	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 529-536	13.4	51
54	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , 2018 , 72, 772-779	5.2	18
53	Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1297-1298	13.4	
52	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000403	6	15
51	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98	4.8	6

50	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018 , 7, CRC01	0.8	2
49	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 116, 318-323	8.7	20
48	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017 , 86, 197-206	7.5	16
47	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514	6.4	14
46	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017 , 2, e000147	6	28
45	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
44	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017 , 37, 315-319	2.3	16
43	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845	5.2	9
42	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
41	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016 , 6, 25195	4.9	19
40	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 30-6	8.7	39
39	First-line chemotherapy for mCRC: review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 607-19	19.4	106
38	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015 , 26, 1188-1194	10.3	112
37	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1283-92	3.5	8
36	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015 , 136, 83-90	7.5	92
35	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015 , 26, 724-730	10.3	117
34	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-657	2.2	5
33	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. <i>Oncotarget</i> , 2015 , 6, 33982-92	3.3	39

32	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1609-18	59.2	663
31	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014 , 14, 322-7	3.5	10
30	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014 , 9, 205-14	5	22
29	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3596-3596	2.2	4
28	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3664-TPS3664	2.2	1
27	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients 2014 , 135-142		
26	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013 , 108, 2549-56	8.7	45
25	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7	10.3	74
24	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. <i>Annals of Oncology</i> , 2013 , 24, iv21	10.3	4
23	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774	3.7	55
22	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
21	Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 71-6	3.8	15
20	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012 , 23, 1370-1371	10.3	7
19	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 1207-1213	10.3	36
18	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 153-160	1	
17	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012 , 23, 2072-2077	10.3	82
16	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. <i>Annals of Oncology</i> , 2012 , 23, 135-141	10.3	60
15	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011 , 11, 247	4.8	61

14	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1262-9	8.7	77
13	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 78, 243-51	7	26
12	Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 21-30	9.7	131
11	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010 , 11, 1247-56	2.6	5
10	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010 , 21, 1565	10.3	32
9	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , 2010 , 11, 845-52	21.7	204
8	Genetic modulation of the Let-7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. <i>Pharmacogenomics Journal</i> , 2010 , 10, 458-64	3.5	102
7	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 58	12.8	41
6	Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. <i>Current Cancer Drug Targets</i> , 2010 , 10, 37-45	2.8	8
5	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 559-66	3.5	5
4	Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 167-81	5.4	6
3	Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 670-4	19.4	3
2	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 101, 715-21	8.7	450
1	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <i>Oncologist</i> , 2008 , 13, 1270-5	5.7	197